Guardant Health’s Shield, a liquid biopsy that screens for colorectal cancer by analyzing a patient blood sample, will compete against stool-based tests already established in the market. Shield could also face new competition from other liquid biopsy companies.
Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
DNA sequencing power house Illumina sued liquid biopsy company Guardant Health, whose founders used to work for Illumina, claiming the two stole information from Illumina to file patents for Guardant. Illumina alleges that one of the executives misappropriated confidential information while he was still on Illumina's payroll.
What draws investors to healthcare startups? In this series in the runup to MedCity INVEST in Chicago, we'll highlight these perspectives. If you're a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to encourage coverage by those payers still on the sidelines.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The study, by US and Korean researchers, found Guardant360's detection of MSI-H/dMMR "highly concordant" with that of standard tissue biopsy, including in a subset of gastric cancer patients who responded to immunotherapy.
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
An investment analyst wrote that physicians see the results as potentially ushering in a "liquid-first" testing paradigm, but the liquid biopsy market is likely to include several or even more than a dozen major players.
Judy Smythe, Bardia Akbari and Niv Caviar have been named as the company's chief operating officer, senior vice president of clinical operations and chief financial officer, respectively.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."
Investment could be called frothy, but hasn't reached bubble territory yet, SVB report author says.
In a new analysis, Accenture dives deeper into digital health funding. The assessment includes a prediction that annual investment in digital health startups will reach $7 billion by the end of 2017.
A family member's liquid biopsy test, gene testing and a journey into coverage decisions and clinical guidelines reveal how difficult the reimbursement path is for these emerging technologies.
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed "Guardant 1 million," the push will be financed with $360 million in new financing from a broad syndicate of investors.